Evaluation of serum placental growth factor in predicting pregnancy outcomes in women with suspected pre-eclampsia

Fariba Kahnamouei-aghdam, Farhad Pourfarzi, Samaneh Ehsani


Background:Amount of Placental Growth Factor (PLGF) in the blood at 9 to 11 weeks before the onset of clinical signs of pre-eclampsia is reduced. So, diagnostic tests based on the pathophysiology of disease such as PLGF as an ideal marker for early screening in the diagnosis and management of women with preeclampsia, may be useful. The aim of this study was to investigate PLGF in predicting pregnancy outcome in women with suspected pre-eclampsia.

Methods: A case - control study was conducted on 30 women with suspected pre-eclampsia and 101 healthy pregnant women which selected randomly among all pregnant women referred to clinic. Both groups were followed until pregnancy termination and in terms of pregnancy outcomes (Gestational age, Type of delivery and birth weight). Two groups were matched in terms of age, weight, education, substance abuse and socio-economic status. Placental growth factor assay was done by ELISA kit. Data collected by a checklist and analyzed by statistical methods in SPSS.19.

Results:The mean PLGF level was lower for women who experienced preeclampsia compared with healthy women (71.5 pg/ml vs 272.1 pg/ml, p=0.001). Also, PLGF concentrations was very low in women with preeclampsia who had a preterm birth prematurity.

Conclusions:Study findings identified PlGF as an ideal, simple and non-invasive marker for primary screening at prenatal care for women at risk of pre-eclampsia.


Placental growth factor, Preeclampsia, Pregnancy outcome

Full Text:



Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33:130-7.

Wallis AB, Saftlas AF, Hsia J, Atrash HK. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. Am J Hypertens. 2008;21:521-6.

Gaio DS, Schmidt MI, Duncan BB. Hypertensive disorders in pregnancy: frequency and associated factors in a cohort of Brazilian women. Hypertension in pregnancy. 2001;20:269-81.

Sibai B, Dekker G, Kupferminc M. Preeclampsia. Lancet. 2005;365:785-99.

Dekker G, Sibai B. Primary, secondary, and tertiary prevention of preeclampsia. Lancet. 2001;357:209-15.

Krauss T, Pauer HU, Augustin HG. Prospective analysis of placenta growth factor (PLGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy. 2004;23:101-11.

Verlohren S, Herraiz I, Lapaire O. The sFlt-1/PLGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. American J Obstetr Gynecol. 2012;206;58.e1-58.e8.

Rana S, Powe CE, Salahuddin S. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012;125:911-9.

Perni U, Sison C, Sharma V. Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension. 2012;59:740-6.

Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-83.

Espinoza J, Romero R, Nien JK. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol. 2007;196:326.e1-326.e13.

Savvidou MD, Akolekar R, Zaragoza E. First trimester urinary placental growth factor and development of pre-eclampsia. BJOG. 2009;116: 643-7.

Zaragoza E, Akolekar R, Poon LC. Maternal serum placental growth factor at 11-13 weeks in chromosomally abnormal pregnancies. Ultrasound Obstet Gynecol. 2009;33:382-6.

Pandya P, Wright D, Syngelaki A. Maternal serum placental growth factor in prospective screening for aneuploidies at 8–13 weeks’ gestation. Fetal Diagn Ther. 2012;31:87-93.

Akolekar R, Zaragoza E, Poon LC. Maternal serum placental growth factor at 11+0 to 13+6weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2008;32:732-9.

Poon LC, Zaragoza E, Akolekar R. Maternal serum placental growth factor (PLGF) in small for gestational age pregnancy at 11(+0) to 13(+6) weeks of gestation. Prenat Diagn. 2008;28:1110-5.

Akolekar R, Syngelaki A, Sarquis R. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn. 2011;31:66-74.

Karagiannis G, Akolekar R, Sarquis R. Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks. Fetal Diagn Ther. 2011;29:148-54.

Lai J, Garcia-Tizon Larroca S, Peeva G. Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks’ gestation. Fetal Diagn Ther. 2014;35:240-8.

Chaiworapongsa T, Romero R, Savasan ZA. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med. 2011;24:1187-1207.

Rana S, Powe CE, Salahuddin S. Angiogenic factors and the risk of adverse outcomes in women with suspected pre-eclampsia. Circulation. 2012;125: 911-9.

Sibiude J, Guibourdenche J, Dionne MD. Placental growth factor for the prediction of adverse outcomes in patients with suspected pre-eclampsia or intrauterine growth restriction. PLoS One. 2012;7:e50208..

Chappell LC, Duckworth S, Seed PT. Diagnostic accuracy of placental growth factor in women with suspected pre-eclampsia: a prospective multicenter study. Circulation. 2013;128:2121-31.

Benton SJ, Hu Y, Xie F. Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. Am J Obstet Gynecol. 2011;205:469?e1-8.

Knudson UB, Kronborg CS, von Dadelson P. A single rapid pointof-care placental growth factor determination as an aid in the diagnosis of preeclampsia. Preg Hyper: An Int J Women’s Card Health. 2012;2:8-15.

Maynard SE, Venkatesha S, Thadhani R, Karumanchi A. Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of eeclampsia. Pediatr Res. 2005;57:2-5.

Gullai N, Stenczer B, Molvarec A. Evaluation of rapid and simple placental growth factor in hypertensive disorders of pregnancy. Hypertens Res. 2013;36:457-62.

Aljebory H, Shaker H. The role of maternal serum placental growth factor level in predicting delivery within two weeks in preeclamptic women. Mustansiriya Medic J. 2016;15:30-7.